OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$10.12 USD
+1.32 (15.00%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $10.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.12 USD
+1.32 (15.00%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $10.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Zacks News
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
by Zacks Equity Research
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
by Zacks Equity Research
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 7.69% and 2.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for January 11th
by Zacks Equity Research
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.
OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 41.3% upside potential for OptimizeRx Corp. (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks.com featured highlights Freshpet, OptimizeRx and Pinterest
by Zacks Equity Research
Freshpet, OptimizeRx and Pinterest have been highlighted in this Screen of The Week article.
3 Stocks Worth a Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Freshpet (FRPT), OptimizeRx (OPRX) and Pinterest (PINS) at the moment for solid earnings acceleration.
Why OptimizeRx Corp. (OPRX) Might be Well Poised for a Surge
by Zacks Equity Research
OptimizeRx Corp. (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%
by Zacks Equity Research
The mean of analysts' price targets for OptimizeRx Corp. (OPRX) points to a 47.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -12.50% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sea Limited (SE) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Sea Limited's (SE) fourth-quarter 2022 results are likely to benefit from a stable Free Fire user base and the growing popularity of Shopee.
VMware (VMW) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
VMware (VMW) delivered earnings and revenue surprises of 7.58% and 2.16%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy OptimizeRx (OPRX) Ahead of Earnings?
by Zacks Equity Research
OptimizeRx (OPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Oracle (ORCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Oracle (ORCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avid Technology (AVID) Q4 Earnings Lag Estimates
by Zacks Equity Research
Avid (AVID) delivered earnings and revenue surprises of -4.26% and 1.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Commvault Systems (CVLT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Commvault (CVLT) delivered earnings and revenue surprises of 14% and 0.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -60% and 18.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?